Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$11.9 million.

  • Enanta Pharmaceuticals' Consolidated Net Income rose 4644.24% to -$11.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$71.4 million, marking a year-over-year increase of 3180.41%. This contributed to the annual value of -$81.8 million for FY2025, which is 2941.25% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Consolidated Net Income stood at -$11.9 million for Q4 2025, which was up 4644.24% from -$18.6 million recorded in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Consolidated Net Income peaked at -$11.9 million during Q4 2025, and registered a low of -$39.1 million during Q2 2023.
  • Moreover, its 5-year median value for Consolidated Net Income was -$28.4 million (2023), whereas its average is -$27.5 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 50391.34% in 2021, then soared by 4644.24% in 2025.
  • Enanta Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then fell by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then soared by 46.44% to -$11.9 million in 2025.
  • Its last three reported values are -$11.9 million in Q4 2025, -$18.6 million for Q3 2025, and -$18.3 million during Q2 2025.